Bicara Therapeutics (BCAX) Total Liabilities (2023 - 2026)

Bicara Therapeutics' Total Liabilities history runs 4 years deep, the most recent figure standing at $39.6 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 107.33% year-over-year to $39.6 million in Q1 2026; TTM through Mar 2026 was $39.6 million, a 107.33% increase from a year earlier, with the FY2025 full-year figure at $29.5 million, up 63.03% from the prior year.
• Total Liabilities climbed to $39.6 million in Q1 2026 per BCAX's latest filing, from $29.5 million in the prior quarter.
• Across five years, Total Liabilities topped out at $39.6 million in Q1 2026 and bottomed at $14.6 million in Q3 2024.
• The 4-year median for Total Liabilities is $18.8 million (2025), against an average of $22.1 million.
• Across the five-year window, Total Liabilities grew 17.11% in 2024 and jumped 107.33% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $15.5 million in 2023, then grew by 17.11% to $18.1 million in 2024, then soared by 63.03% to $29.5 million in 2025, then soared by 34.19% to $39.6 million in 2026.
• Per Business Quant, the three latest BCAX Total Liabilities figures stand at $39.6 million (Q1 2026), $29.5 million (Q4 2025), and $21.9 million (Q3 2025).